Press Release: Tarveda : Tarveda Therapeutics Publishes Preclinical Study Evaluating HSP90 Binding Miniature Drug Conjugate with Pan-PI3K Payload in Solid Tumors
WATERTOWN, Mass.--(BUSINESS WIRE)--Tarveda Therapeutics announces the publication of a preclinical study in Molecular Cancer Therapeutics.
Read full article »
Tarveda is a biopharmaceutical company that discovers and develops miniaturized drug conjugates for the treatment of solid tumor malignancies.
Read more